Ana Ruiz-Garcı́a - Concepedia

Author

Ana Ruiz-Garcı́a

Also Known As

A Ruiz-Garcia, A Ruiz‐Garcia, A. Ruiz, A. Ruiz-Garcia, A. Ruiz-García, A. Ruiz‐Garcia, Ana Ruiz, Ana Ruiz-Garcia, Ana Ruiz-GarcÍa, Ana Ruiz-Garcı́a

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Universitat de València Pfizer (Italy)Metrum Research Group (United States)The University of Texas MD Anderson Cancer Center

About

Ana Ruiz-Garcı́a is an author at Pfizer (United States) specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	19	941
2	Health Sciences	3	3	61
3	Biochemistry	2	2	51
4	Natural Sciences	1	1	29
5	Public Health	1	1	23

Ana Ruiz-Garcı́a

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Sandrine Faivre, Éric Raymond, Éveline Boucher, The Lancet Oncology HepatologyMedicinePharmacologyPathologyPhase Ii Study	2009	288
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski, Journal of Clinical Oncology	2012	265
PAMPA—a drug absorption in vitro model Marival Bermejo, Alex Avdeef, Ana Ruiz-Garcı́a, European Journal of Pharmaceutical Sciences Pharmacological StudyMedicinePampa—a Drug AbsorptionDrug AbsorptionPharmacology	2004	203
Phase II study of sunitinib as second-line treatment for advanced gastric cancer Yung‐Jue Bang, Yoon‐Koo Kang, Won Ki Kang, Investigational New Drugs	2010	193
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge, Cancer	2014	142
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, Investigational New Drugs	2012	63
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach Wan Sun, Peter J. O’Dwyer, Richard S. Finn, The Journal of Clinical Pharmacology ImmunologyPharmacotherapyMetronomic ChemotherapyPharmacodynamic ModelingPalbociclib Treatment	2017	49
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study Martin Reck, Norbert Frickhofen, S. Cedrés, Lung Cancer Dose-escalation StudyOncologyMedicineImmune Checkpoint InhibitorAnti-cancer Agent	2010	46
A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers Carlo L. Bello, Evan Smith, Ana Ruiz-Garcı́a, Cancer Chemotherapy and Pharmacology MedicineMass Balance StudyHealthy Male VolunteersPharmacology	2013	44
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer Chandrasekar Durairaj, Ana Ruiz-Garcı́a, Eric Gauthier, Anti-Cancer Drugs Breast OncologyCancer ManagementPharmacotherapyQtcf ValuesAdvanced Breast Cancer	2018	44

Page 1